Valneva SE (VALN) Operating Leases (2020 - 2026)
Valneva SE (VALN) posted Operating Leases of $28.6 million for Q1 2026, down 3.04% sequentially from $29.5 million in Q4 2025, and little changed YoY from $28.7 million in Q1 2025.
Valneva SE (VALN) Operating Leases (2020 - 2026) Analysis & Trends
Valneva SE has reported Operating Leases for 7 years, with the latest figure at $28.6 million in Q1 2026.
- Quarterly Operating Leases changed 0.27% year-over-year to $28.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.6 million (changed 0.27% YoY) and the FY2025 annual result came in at $29.5 million, down 5.82% from the prior year.
- Operating Leases slipped to $28.6 million in Q1 2026 per VALN's latest filing, from $29.5 million in the prior quarter.
- Over five years, Operating Leases peaked at $59.1 million in Q1 2022 and troughed at $28.6 million in Q2 2024.
- A 5-year average of $36.1 million and a median of $30.3 million in 2023 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2025: Operating Leases tumbled 46.33% in 2023, then advanced 4.13% in 2025.
- Over 5 years, Operating Leases stood at $54.7 million in 2022, then sank by 37.07% to $34.4 million in 2023, then dropped by 10.09% to $30.9 million in 2024, then retreated by 4.61% to $29.5 million in 2025, then decreased by 3.04% to $28.6 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $28.6 million, $29.5 million, and $29.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.25 Mn |
| Mar 31, 2026 | 28.60 Mn |
| Dec 31, 2025 | 29.50 Mn |
| Sep 30, 2025 | 29.75 Mn |
| Jun 30, 2025 | 29.31 Mn |
| Mar 31, 2025 | 28.68 Mn |
| Dec 31, 2024 | 30.93 Mn |
| Sep 30, 2024 | 28.57 Mn |
| Jun 30, 2024 | 28.57 Mn |
| Mar 31, 2024 | 29.93 Mn |
| Dec 31, 2023 | 34.40 Mn |
| Sep 30, 2023 | 30.32 Mn |
| Jun 30, 2023 | 30.36 Mn |
| Mar 31, 2023 | 31.72 Mn |
| Dec 31, 2022 | 54.66 Mn |
| Sep 30, 2022 | 53.08 Mn |
| Jun 30, 2022 | 55.41 Mn |
| Mar 31, 2022 | 59.11 Mn |
| Dec 31, 2021 | 65.00 Mn |
| Dec 31, 2020 | 62.10 Mn |